| Product sales | 2.33M |
| Contract R & D and grant revenues | |
| Total revenues | 3.63M |
| Cost of goods sold | 1.09M |
| Cost of R & D and grant revenues | 352.03K |
| Total cost of revenues | 1.44M |
| Gross profit | 2.18M |
| Selling and marketing | 380.56K |
| Research and development | 161.17K |
| General and administrative | 1.21M |
| Costs associated with exit or disposal activities (note 9) | |
| Total expenses | 1.75M |
| Operating income (loss) | 435.71K |
| Other income | 0 |
| Interest expense | -2.37K |
| Net loss | 433.53K |
| Accreted dividends on redeemable preferred and redeemable common stock | |
| Net loss attributable to common stockholders | |
| Net loss per share, basic (in dollars per share) | 0.01 |
| Net loss per share, diluted (in dollars per share) | 0.01 |
| Weighted average shares outstanding, basic (in shares) | 54.85M |
| Weighted average shares outstanding, diluted (in shares) | 60.37M |
| Net loss | |
| Other comprehensive income (loss)-foreign currency translation | |
| Total comprehensive loss | |